Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / Showe 29-gene signature for lung cancer

Showe 29-gene signature for lung cancer



QA State: Curated
Short Name:
HGNC Name:

A 29-gene peripheral blood gene expression signature that separates patients with non-small cell lung cancer (NSCLC) tumors and patient controls with 86% accuracy (91% sensitivity, 80% specificity). Subjects were primarily smokers and former smokers. The 29 genes, minus one that did not match a gene symbol in the naming database: RSF1, DYRK2, YY1, C19orf12, THEM2, TRIO, MYADM, BAIAP2, ROGDI, DNAJB14, BRE, TMEM41A, C9orf64, FAM110A, PCNXL2, REST, C19orf62, C13orf27, ASCC3, SLC1A5, PTPLAD1, MRE11A, GTPBP10, SERPINI2, CREB1, CCDC53, USP48, ZSCAN2

Panel Details

No member markers defined for this panel.


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: One
QA State: Curated


This gene expression signature found in peripheral blood mononuclear cells (PBMCs) can distinguish patients with early-stage NSCLC from appropriate at-risk controls with nonmalignant lung diseases common to both patient and control classes.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.


No associated resources found.

2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 12/02/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh ( no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.